Newsroom

LATEST PUBLICATIONS

Clonality and Measurable Residual Disease (MRD) Testing on the Illumina NextSeq Sequencers

2026-04-20T09:08:04-07:00June 21st, 2024|

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

2026-04-20T09:04:28-07:00May 2nd, 2024|

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

2024-03-26T13:55:01-07:00March 20th, 2024|

Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal residual disease detection in Chinese patients with multiple myeloma

2026-04-20T09:07:34-07:00March 19th, 2024|

Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing–Based Clonality Testing in B-Cell and Plasma Cell Neoplasms

2026-04-20T09:06:43-07:00March 1st, 2024|

Invivoscribe Diagnostic Technologies (Shanghai) Co. Ltd. Receives CAP Accreditation to Support Clinical Research Testing for Pharmaceutical Partners in China

2023-02-23T06:28:40-08:00February 23rd, 2023|

Invivoscribe Appoints Masato Sasaki as General Manager of LabPMM, GK (Japan)

2023-02-01T21:02:16-08:00February 1st, 2023|

Invivoscribe files sPMA with the FDA for use of the LeukoStrat CDx FLT3 Mutation Assay to Select Patients with Newly Diagnosed FLT3-ITD Positive AML

2022-10-24T14:57:12-07:00October 24th, 2022|

Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio’s Investigational Compound Being Developed for Patients with AML

2026-03-08T22:24:18-07:00August 16th, 2022|

Hitachi High-Tech and Invivoscribe partner to advance molecular diagnostics and precision medicine

2025-08-26T08:08:16-07:00May 9th, 2022|

SOHO

Sep 9-12, 2026
Houston, TX
Exhibiting
Visit Conference Website

European Congress of Pathology (ECP 2026)

Sep 12-16, 2026
Stockholm, Sweden
Attending
Visit Conference Website

AGBT Precision Health

Sep 14-16, 2026
San Diego, CA
Exhibiting
Visit Conference Website

iwAL Meeting

Sep 18-20, 2026
Cambridge, MA
Attending
Visit Conference Website

NCCN Annual Hematologics Malignancies Congress

Sep 18-19, 2026
New York, NY
Attending
Visit Conference Website

Newsroom

Newsroom

LATEST PUBLICATIONS

Clonality and Measurable Residual Disease (MRD) Testing on the Illumina NextSeq Sequencers

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal residual disease detection in Chinese patients with multiple myeloma

Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing–Based Clonality Testing in B-Cell and Plasma Cell Neoplasms

LATEST PRESS

Invivoscribe Diagnostic Technologies (Shanghai) Co. Ltd. Receives CAP Accreditation to Support Clinical Research Testing for Pharmaceutical Partners in China

Invivoscribe Appoints Masato Sasaki as General Manager of LabPMM, GK (Japan)

Invivoscribe files sPMA with the FDA for use of the LeukoStrat CDx FLT3 Mutation Assay to Select Patients with Newly Diagnosed FLT3-ITD Positive AML

Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio’s Investigational Compound Being Developed for Patients with AML

Hitachi High-Tech and Invivoscribe partner to advance molecular diagnostics and precision medicine

CONFERENCES

SOHO

European Congress of Pathology (ECP 2026)

AGBT Precision Health

iwAL Meeting

NCCN Annual Hematologics Malignancies Congress

Global Search

SEARCH BY KEYWORD

Global Search

SEARCH BY KEYWORD

Looking for Product Documents?
Try our New Document Search Feature ⟶

Looking for Product Documents?
Try our New Document Search Feature ⟶